Humacyte, Inc.

Changes to the Board of Directors

On March 26, 2026, Todd Pope notified the Company that he intends not to stand for re-election at the Company’s 2026 annual meeting of stockholders. Mr. Pope’s decision was not the result of any disagreement between Mr. Pope and the Company, its management, board of directors or any committee thereof, or with respect to any matter relating to the Company’s operations, policies or practices. Rather, Mr. Pope’s growing outside professional and business obligations led to his decision not to stand for re-election. Mr. Pope has been a valued member of the Board, and the Company thanks him for his contributions.

Director and Officer Trading Arrangements

On October 13, 2025, Laura E Niklason, the Company’s President and Chief Executive Officer, had a previously disclosed trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act automatically terminate in accordance with its terms upon the expiration date of the plan. The trading arrangement provided for the potential sale of up to 200,000 shares of Common Stock.

On December 8, 2025, Dale A. Sander, the Company’s Chief Financial Officer, adopted a trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (the “Sander 10b5-1 Plan”). The Sander 10b5-1 Plan provides for the potential sale of up to 311,100 shares of Common Stock that may be received pursuant to equity compensation awards, with the first possible trade date on May 16, 2026. The Sander 10b5-1 Plan terminates automatically on the earlier of the completion of all transactions contemplated by the plan, or June 1, 2027.

On December 8, 2025, Shamik Parikh, the Company’s Chief Medical Officer, adopted a trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (the “Parikh 10b5-1 Plan”). The Parikh 10b5-1 Plan provides for the potential sale of up to 311,100 shares of Common Stock that may be received pursuant to equity compensation awards, with the first possible trade date on May 16, 2026. The Parikh 10b5-1 Plan terminates automatically on the earlier of the completion of all transactions contemplated by the plan, or June 1, 2027.

During the three months ended December 31, 2025, except as described above, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted orterminated any “Rule 10b5-1 trading arrangement” or any “non Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.